Abstract
Photodynamic therapy (PDT) is an effective local treatment modality as a cancer-specific laser ablation in malignancy of some organs including digestive tracts or bile duct. In Japan, PDT has been applied at the early period after the first clinical induction in 1980’s. Although the useful efficacy was clarified, PDT has not been fully applied because of the phototoxicity of the porfimer sodium. The next generated talaporfin-sodium was used for PDT, in which phototoxicity was reduced and, however, the clinical efficacy for digestive tract malignancy has not yet been clarified. By proceeding the experimental and clinical trials, it is necessary to clarify the evidence of efficacy as a local powerful treatment with the conventional surgery, brachiotherapy and chemotherapy in the future step.
Highlights
IntroductionPhotodynamic therapy (PDT) has been clinically applied for human carcinomas by Dougherty et al [1]
Induction of Photodynamic Therapy for Digestive Tract Carcinoma in JapanPhotodynamic therapy (PDT) has been clinically applied for human carcinomas by Dougherty et al [1]since 1978
In the case of a contra-indication for Endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD), argon plasma coagulation could be applied at a lower cost than P-PDT [12]
Summary
Photodynamic therapy (PDT) has been clinically applied for human carcinomas by Dougherty et al [1]. Since the 1990s, there have been many advances of PDT in the treatment of digestive tract carcinomas, such as in the esophagus, stomach, and bile duct, in Japanese series [2,3,4,5,6,7,8]. In these series, PDT using 2 mg per kg body weight of porfimer sodium (Photofrin®; Wyeth-Takeda, Tokyo, Japan) was used as a photosensitizer. By the above investigators’ efforts, PDT has been approved as a radical treatment in the digestive tract for superficial carcinoma of the esophagus and stomach under the national health insurance system by the Ministry of Health and Welfare, Japan, since 1994
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
